Does alpha-MSH act on all five melanocortin receptors?

No. MC2R primarily recognises ACTH peptides only. The other four recognise alpha-MSH.

Is selectivity between the others possible?

Yes — structure-activity work has pursued it since the 1990s, and setmelanotide and afamelanotide are selective enough to hold assessed indications.

MT-2 (Melanotan II)

Alpha-MSH Engages Four of Five, Not All of Them

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

There are five melanocortin receptors. MC2R primarily recognises ACTH peptides only; the other four — MC1R, MC3R, MC4R and MC5R — all recognise alpha-MSH. That distinction is routinely lost when the family is described as one group.

Key facts

Receptors: MC1R through MC5R
MC1R and MC2R: Cloned first
MC2R recognises: ACTH peptides, essentially alone
Recognise alpha-MSH: MC1R, MC3R, MC4R, MC5R
Source: Hruby 1995 (PMID 7658432)
Consequence: Selectivity concerns four receptors, not five

How the family was assembled

Hruby and colleagues describe the sequence in their 1995 paper: cloning of the MSH and ACTH receptors produced MC1-R and MC2-R, and that led to identification of three more — MC3-R, MC4-R and MC5-R. The family was discovered in two stages, with the two functionally obvious receptors found first.

The distinction that gets flattened

Their abstract states it directly: the MC2 receptor primarily recognises only ACTH peptides, while the other four all recognise alpha-MSH. So alpha-MSH is not a ligand for the whole family. MC2R belongs to ACTH, which is why it sits in the adrenal cortex driving steroid production rather than in tissues alpha-MSH acts on.

Research material referenced

MT-2 10mg — third-party HPLC tested

View — £19.99

Why that matters for a non-selective compound

A compound built on an alpha-MSH scaffold has four receptors available to it, not five. That is a narrower problem than the usual framing suggests — and still a substantial one, because those four sit in skin, brain and exocrine tissue and do unrelated things.

What each of the four does

MC1R on melanocytes governs pigmentation. MC3R and MC4R are largely central and participate in energy balance, with MC4R the better characterised. MC5R is associated with exocrine function. One ligand family, four receptors, four largely unrelated physiological domains.

Why selectivity is achievable in principle

Because the receptors differ enough for structure-activity work to separate them. Hruby's 1995 paper reports selectivity at specific melanocortin receptors, and Mayorov's 2008 follow-up examines cyclic lactam analogues targeting human melanocortin receptors specifically. Selectivity is an engineering target that has been pursued, not an impossibility.

And why it matters which compounds achieved it

Setmelanotide is an MC4R agonist approved for a specific genetic obesity indication. Afamelanotide is approved for a photoprotection indication. Both are selective enough to have an assessed indication. A compound described as non-selective is a compound where that work was not done or not completed.

Quick reference

Receptor	Principal ligand	Main association
MC1R	alpha-MSH	Melanocytes, pigmentation
MC2R	ACTH only	Adrenal cortex
MC3R	alpha-MSH	Central, energy balance
MC4R	alpha-MSH	Central, energy balance
MC5R	alpha-MSH	Exocrine tissue

Extended research context

The MT-2 (Melanotan II) deep dive

Deep dive: the identifier collision that points the wrong way

This site has now found several plausible-looking identifiers that resolve to the wrong molecule. A PubChem record for tirzepatide cited as retatrutide. Thymosin beta-4's CAS quoted as TB-500's. An unrelated organic acid returned for KPV. This one is the most consequential of the set, and the reason is direction. Searching PubChem for melanotan returns CID 16197727 - afamelanotide, at 1,646.8 Da for C78H111N21O19. That is Melanotan I, a linear thirteen-residue peptide, and it is an APPROVED MEDICINE, marketed as Scenesse for erythropoietic protoporphyria. Melanotan II is CID 92432: cyclic, seven residues, 1024.2 Da, 622 Da lighter, and assessed by no regulator anywhere. So the wrong record does not merely mislead about mass. It resolves from an unlicensed compound toward a licensed one, and the sequential naming - I and II - makes them look like versions of a single product rather than the structurally distinct compounds they are. Anyone verifying a certificate by searching the bare name lands on an approved drug's record and may never notice which compound it names.

Deep dive: four stability features in seven residues

PubChem's IUPAC name for CID 92432 is unusually complete and reads as a full specification: N-acetyl-L-norleucyl-L-alpha-aspartyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-L-lysinamide, cyclic (2-7)-peptide. Unpack it and there are four independent protease-resistance features in a molecule of seven residues. A lactam bridge joins the aspartate side chain at position 2 to the lysine side chain at position 7, closing the ring - which both locks conformation for receptor engagement and eliminates the free termini exopeptidases require. Position 4 is D-phenylalanine, the mirror image of the natural form, and proteases are stereospecific enough that they largely cannot process it. The N-terminus is acetylated and the C-terminus amidated, capping both ends. And position 1 is norleucine, which is not among the twenty proteinogenic amino acids at all - so even setting aside the cyclisation and the D residue, this peptide could never have been a gene product. It is a fully synthetic construction rather than a modified natural sequence, and it is among the most chemically robust compounds in this catalogue as a direct result.

Deep dive: why the safety literature is included rather than omitted

There is a published dermatological literature here, and the editorial choice was to state it. Reid and colleagues documented atypical melanocytic naevi following melanotan injection in the Irish Medical Journal in 2013. Eijmael and colleagues published a risk review in the Nederlands Tijdschrift voor Geneeskunde in 2022 - a national medical journal considering the topic worth addressing directly. Case reports have a real limitation: they establish an observation without a denominator, so they cannot establish causation or incidence, which is the same constraint that applies to pharmacovigilance disproportionality signals. But that limitation cuts both ways. A case report is not proof of harm and it is not dismissible either. What makes the absence of better data significant here is that no regulator has assessed this compound - so there is no label, no contraindications, no adverse event reporting requirement and no monitoring framework. The information that would normally exist for an injectable product simply does not, and what is available instead is what individual clinicians chose to publish after seeing something. Presenting the compound without that context would give an incomplete picture of what is actually known.

Research applications

▸Melanocortin receptor pharmacology and selectivity research
▸Cyclic peptide and lactam bridge design studies
▸D-amino acid substitution and protease resistance research
▸Structure-activity work on constrained peptide analogues
▸Comparative work on alpha-MSH derivatives
▸Analytical method development for cyclic peptides

Handling checklist

✓Verify against CID 92432, 1024.2 Da, C50H69N15O9, CAS 121062-08-6
✓Never verify by searching 'melanotan' alone - that returns afamelanotide at 1,646.8 Da
✓Require stereochemistry on the certificate - D-Phe4 is not detectable by mass
✓Protect from light; tryptophan at position 6 is photochemically reactive
✓Store lyophilised, cold, dry and dark
✓Expect no disulfide or oxidation satellites - no cysteine, no methionine
✓Quantification at 280 nm is available thanks to the tryptophan

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Searching PubChem for 'melanotan' to verify identity

Fix: That returns CID 16197727, afamelanotide, at 1,646.8 Da - an approved medicine and a different molecule. Use CID 92432 or search Melanotan II with the numeral.

✗ Treating Melanotan I and II as versions of one compound

Fix: They differ by 622 Da, by six residues, and by whether the peptide is cyclic or linear. Only Melanotan I has been assessed by regulators.

✗ Reading afamelanotide's approval as covering MT-2

Fix: Different molecule, different structure, different evidence, different assessment. Nothing transfers.

✗ Accepting a sequence written without stereochemistry

Fix: L- and D-phenylalanine have identical mass. A peptide with the L form at position 4 is a different compound that mass spectrometry cannot distinguish.

✗ Assuming a non-selective agonist affects only its intended receptor

Fix: Five melanocortin receptors share binding surfaces across different tissues. Engagement elsewhere is the same pharmacology in another place, not a side reaction.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Does alpha-MSH act on all five melanocortin receptors?: No. MC2R primarily recognises ACTH peptides only. The other four recognise alpha-MSH.
Why is MC2R different?: It is the ACTH receptor, sitting in the adrenal cortex driving steroid production rather than in the tissues alpha-MSH acts on.
Is selectivity between the others possible?: Yes — structure-activity work has pursued it since the 1990s, and setmelanotide and afamelanotide are selective enough to hold assessed indications.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More MT-2 (Melanotan II) articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum